Netherlands· NL-b4e00a680fed

Mycobutin, capsules 150 mg

A rifabutin product containing rifabutine, registered in Netherlands by Pfizer B.V.. The same ATC class is registered in 15 of our 19 countries.

ATC J04AB04

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about rifabutineAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Rifabutin is registered in 15 of 19 countries.

Countries holding a registration under ATC J04AB04 (rifabutin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search rifabutin products by name

Rifabutin · ATC J04AB04

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rifabutin costs, country by country.

Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Rifabutin · price per daily dose (0.15 g)

USD · FX 28 Sept 2026

CH Switzerland$5.51

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RIFABUTINE
Manufacturer: Pfizer B.V.
Country: Netherlands (NL)
ATC code: J04AB04
ATC class: Rifabutin
Defined daily dose: 0.15 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
16740

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

278 interactions on record for rifabutin.

Graded by severity as the source publishes them — 91 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check rifabutin against other medicines How interaction checks work

Rifabutin · interactions on record

278 records

91 severe
146 moderate
8 minor

Most severe, free to view

RolapitantA04AD14severe
EliglustatA16AX10severe
DicoumarolB01AA01severe
WarfarinB01AA03severe

33 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rifabutin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rifabutin products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

Austria · Mycobutin
Belgium · Mycobutin
Czechia · Mycobutin
Germany · Mycobutin
Spain · Ansatipin
Finland · Ansatipin
France · Ansatipine
United Kingdom (Northern Ireland) · Mycobutin, Rifabutin Pfizer
Ireland · Mycobutin
Italy · Mycobutin
Luxembourg · Mycobutin
Portugal · Mycobutin
Sweden · Ansatipin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/bb91208f-4a08-4557-b834-dab7bba6caf9
GET /v1/drugs/bb91208f-4a08-4557-b834-dab7bba6caf9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h16740_smpc.pdf",
  "strength": null,
  "atc_label": "Rifabutin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg16740",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "GELATINE (E 441)",
    "IJZEROXIDE ROOD  (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "SILICIUMDIOXIDE, GEHYDRATEERD (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "RIFABUTINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h16740.pdf",
  "authorised_at": "1995/07/17",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "16740",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about rifabutin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console